Prime Therapeutics and Magellan Rx to present three managed care pharmacy research studies at AMCP Nexus

Impact: All lines of business

On Monday, Oct. 16, Prime/Magellan Rx will publish a press release announcing three research studies that will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus event next week.

“Our aim is to improve health outcomes and reduce health care costs, which is why it’s particularly important for our teams to research these conditions associated with high costs of care,” said Pat Gleason, PharmD, assistant vice president for health outcomes at Prime.

The following studies will be featured at this year’s event:

• Identification and Management of Duplicate Therapy Involving Incretin-Targeting Therapies for Diabetes and Weight Loss
• Real-World Outcomes Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Large B-Cell Lymphoma
• Evaluating the Impact of a Comprehensive Hemophilia Management Program on Utilization and Clinical Outcomes

Prime researchers also will present several sessions during AMCP Nexus. More information about these presentations can be found on Prime Therapeutics’ events page or the AMCP Nexus website.